| 2018 | Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck | 고윤우, 김진아, 김혜련, 윤선옥, 조병철, 최은창, 홍민희 |
| 2018 | A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer | 금기창, 김다희, 김세헌, 김혜련, 조남훈, 조병철 |
| 2018 | Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice
| 김혜련, 안병철, 조병철, 홍민희 |
| 2018 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions | 조병철 |
| 2018 | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
| 조병철 |
| 2018 | Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. | 김혜련, 심효섭, 조병철, 표경호, 홍민희 |
| 2018 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. | 김혜련, 안병철, 조병철, 홍민희 |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | 김대준, 김진아, 김혜련, 박성용, 백순명, 심효섭, 윤미란, 이진구, 이한나, 조병철, 표경호, 홍민희 |
| 2017 | Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
| 김대준, 이익재, 이창걸, 장지석, 조병철, 차지혜 |
| 2017 | Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma | 김은경, 김혜련, 윤선옥, 조병철, 허수진 |
| 2017 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. | 김주항, 김혜련, 심효섭, 임선민, 조병철 |
| 2017 | Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042) | 조병철 |
| 2017 | Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer | 조병철 |
| 2017 | Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
| 김혜련, 서창옥, 이창걸, 장종희, 조병철 |
| 2017 | Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer | 김혜련, 심효섭, 조병철, 차윤진 |
| 2017 | A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017)
| 김주항, 김혜련, 정인경, 조병철 |
| 2017 | Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma | 금기창, 김세헌, 김혜련, 박영민, 조남훈, 조병철 |
| 2017 | Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers | 조병철 |
| 2017 | Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
| 김혜련, 심효섭, 이진구, 이창영, 정인경, 조병철, 차윤진, 홍민희 |
| 2017 | Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition | 김은경, 김한상, 신상준, 정기양, 정민규, 조병철 |
| 2017 | Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs | 김상우, 김성무, 김혜련, 이충근, 조병철 |
| 2017 | Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer | 강한나, 김상균, 김성무, 김혜련, 김환, 윤미란, 임선민, 조병철, 표경호 |
| 2017 | Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
| 김현주, 신성관, 이상길, 이용찬, 이창걸, 조병철 |
| 2017 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | 조병철 |
| 2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | 김혜련, 조병철 |
| 2017 | Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
| 김지형, 김혜련, 박형순, 심효섭, 이진구, 이창영, 조병철, 차윤진, 허수진, 홍민희 |
| 2017 | Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs? | 조병철 |
| 2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | 김은영, 김진아, 김혜련, 백순명, 심효섭, 이진구, 조병철, 홍민희 |
| 2017 | Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer | 김혜련, 박용구, 장원석, 장진우, 정현호, 조병철 |
| 2017 | Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer | 김혜련, 조병철 |
| 2017 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC) | 조병철 |
| 2017 | Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
| 박영년, 유정은, 임선민, 조병철 |
| 2016 | Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
| 고윤우, 김상우, 김한상, 김혜련, 조병철, 최은창 |
| 2016 | Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
| 김혜련, 윤선옥, 조병철, 조윤아, 허수진 |
| 2016 | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. | 김혜련, 심효섭, 이창영, 조병철, 차윤진 |
| 2016 | PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
| 김대준, 김현기, 김혜련, 김효송, 박준철, 배윤성, 신성관, 이상길, 이용찬, 이창걸, 정현수, 조병철, 허진 |
| 2016 | Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
| 김혜련, 임선민, 조병철 |
| 2016 | ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models | 김혜련, 박혜지, 임선민, 조병철, 표경호, 한주연 |
| 2016 | Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma | 고윤우, 김주항, 김혜련, 이창걸, 조병철, 최은창 |
| 2016 | PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
| 고윤우, 김은경, 김혜련, 윤선옥, 정인경, 조병철, 최은창, 표경호, 허수진, 홍민희 |
| 2016 | Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy | 김주항, 김혜련, 박형순, 이민구, 조병철, 조응혁 |
| 2016 | Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation. | 김준원, 김혜련, 서양권, 이창걸, 조병철, 조재호, 최치환 |
| 2016 | The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma | 금기창, 윤미진, 윤홍인, 이정심, 이창걸, 조병철 |
| 2016 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
| 김상우, 김소라, 김현기, 김혜련, 김효송, 박형순, 이민구, 임선민, 정현철, 조병철 |
| 2016 | Clinical course of stage IV invasive mucinous adenocarcinoma of the lung | 김혜련, 심효섭, 이혜정, 조병철 |
| 2016 | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) | 심효섭, 임선민, 정민규, 조병철, 최종락 |
| 2016 | Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
| 김혜련, 백순명, 조병철, 표경호 |
| 2016 | EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
| 김민환, 김주항, 김혜련, 문용화, 백순명, 임선민, 조병철 |
| 2016 | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer | 조병철 |
| 2016 | Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial | 조병철 |
(Yonsei Health Research Network)
